Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge

Abstract The novel coronavirus 2019 (COVID-19) is clinically characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for a high number of patients needing mechanical ventilation or intensive care units treatment and for the elevated mortality risk. A link...

Full description

Saved in:
Bibliographic Details
Published in:Thrombosis and haemostasis Vol. 120; no. 6; pp. 949 - 956
Main Authors: Violi, Francesco, Pastori, Daniele, Cangemi, Roberto, Pignatelli, Pasquale, Loffredo, Lorenzo
Format: Journal Article
Language:English
Published: Stuttgart · New York Georg Thieme Verlag KG 01.06.2020
Subjects:
Algorithms
Betacoronavirus
Cardiology
Coronavirus Infections - blood
Coronavirus Infections - complications
COVID-19
Fibrin Fibrinogen Degradation Products - analysis
Fibrinolytic Agents - therapeutic use
Humans
Liver Failure - therapy
Pandemics
Partial Thromboplastin Time
Platelet Count
Pneumonia, Viral - blood
Pneumonia, Viral - complications
Prothrombin Time
Review Article
Risk
SARS-CoV-2
Thrombophilia - prevention & control
Thrombophilia - therapy
Thrombosis - prevention & control
Thrombosis - therapy
Treatment Outcome
hypercoagulability
thrombosis
infectious diseases
ISSN:0340-6245, 2567-689X, 2567-689X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The novel coronavirus 2019 (COVID-19) is clinically characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for a high number of patients needing mechanical ventilation or intensive care units treatment and for the elevated mortality risk. A link between COVID-19 and multiorgan failure may be dependent on the fact that most COVID-19 patients are complicated by pneumonia, which is known to be associated with early changes of clotting and platelet activation and artery dysfunction; these changes may implicate in thrombotic-related events such as myocardial infarction and ischemic stroke. Recent data showed that myocardial injury compatible with coronary ischemia may be detectable in SARS-CoV-2 patients and laboratory data exploring clotting system suggest the presence of a hypercoagulation state. Thus, we performed a systematic review of COVID-19 literature reporting measures of clotting activation to assess if changes are detectable in this setting and their relationship with clinical severity. Furthermore, we discussed the biologic plausibility of the thrombotic risk in SARS-CoV-2 and the potential use of an antithrombotic treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:0340-6245
2567-689X
2567-689X
DOI:10.1055/s-0040-1710317